Shots:
- Biocon Biologics has received Health Canada’s NOC for Yesintek & Yesintek IV, biosimilars to Stelara, with approval on Oct 17 and commercial availability expected in mid-October
- Approval was supported by data showing YESINTEK is highly similar to Stelara with no meaningful differences in efficacy, safety, or immunogenicity. It will be offered via the My Biocon Biologics support program in SC forms (45 mg/0.5 mL; 90 mg/mL) and as an IV solution (130 mg/26 mL)
- Yesintek (ustekinumab) and Yesintek IV are fully human IgG1κ mAb targeting the p40 subunit of IL-12 and IL-23, key cytokines in immune-mediated diseases
Ref: Biocon Biologics | Image: Biocon Biologics | Press Release
Related News:- Biocon Biologics and Civica Partner to Launch Private-Label Insulin Glargine in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
